Impact BioMedical Receives Patent for Infectious Disease Control Method
ByAinvest
Monday, Aug 18, 2025 9:38 am ET1min read
IBO--
The 3F™ technology addresses the growing infectious disease market, projected to expand from $21.7B in 2024 to $34B in 2023, with a CAGR of 5.77% [1]. The company is actively pursuing partnerships to commercialize 3F™ technology in the US and globally.
IBO is a biotechnology company specializing in discovering, developing, and patenting innovative healthcare solutions. Its subsidiary, Global BioLife, is researching a universal therapeutic drug platform, a sugar substitute called Laetose, a mosquito repellent fragrance, and an antimicrobial medication called Equivir/Nemovir. The company's strategic partnerships and acquisitions, such as the recent merger with Dr. Ashleys Limited and the acquisition of Celios®, aim to accelerate market development and generate immediate revenue [2, 3].
The successful issuance of this patent demonstrates IBO's commitment to addressing unmet healthcare needs and its ability to deliver unique proprietary technology. As the company continues to grow, investors can expect to see further advancements in its drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases.
References:
[1] https://www.stocktitan.net/news/IBO/
[2] https://www.stocktitan.net/news/IBO/
[3] https://www.stocktitan.net/news/IBO/
Impact BioMedical received a US patent for a method to control infectious diseases. The company, a subsidiary of DSS, Inc., focuses on drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. Its subsidiary, Global BioLife, is researching a universal therapeutic drug platform, a sugar substitute called Laetose, a mosquito repellent fragrance, and an antimicrobial medication called Equivir/Nemovir.
Impact BioMedical Inc. (IBO), a subsidiary of DSS, Inc., has announced the issuance of a U.S. patent for its 3F™ technology platform, which focuses on controlling infectious diseases through plant-based functional fragrances. The patent, valid until December 2038, covers unique compositions with antimicrobial and antiviral properties effective against various pathogens, including E. coli, MRSA, influenza, rhinovirus, and M. tuberculosis [1].The 3F™ technology addresses the growing infectious disease market, projected to expand from $21.7B in 2024 to $34B in 2023, with a CAGR of 5.77% [1]. The company is actively pursuing partnerships to commercialize 3F™ technology in the US and globally.
IBO is a biotechnology company specializing in discovering, developing, and patenting innovative healthcare solutions. Its subsidiary, Global BioLife, is researching a universal therapeutic drug platform, a sugar substitute called Laetose, a mosquito repellent fragrance, and an antimicrobial medication called Equivir/Nemovir. The company's strategic partnerships and acquisitions, such as the recent merger with Dr. Ashleys Limited and the acquisition of Celios®, aim to accelerate market development and generate immediate revenue [2, 3].
The successful issuance of this patent demonstrates IBO's commitment to addressing unmet healthcare needs and its ability to deliver unique proprietary technology. As the company continues to grow, investors can expect to see further advancements in its drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases.
References:
[1] https://www.stocktitan.net/news/IBO/
[2] https://www.stocktitan.net/news/IBO/
[3] https://www.stocktitan.net/news/IBO/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet